Eli Lilly raised its outlook a third time in Q3 2026 earnings
Eli Lilly raised its 2026 revenue outlook to $85B-$87B, its third increase this year. Q3 non-GAAP EPS rose 7% to $7.48, beating estimates. Mounjaro and Zepbound revenues grew 65% and 49% respectively. CEO Ricks cited global demand for these drugs. Lilly stock rose 4% premarket. A judge denied Novo Nordisk's request to halt Lilly's weight-loss drug ads.
How this was made
The 30-second read
Why it matters
The guidance raise is the primary tradable catalyst, with product revenue growth supporting demand expectations while realized price declines and the end of Jardiance milestones add caution around margin and future growth composition.
Market read
Traders can reassess near-term expectations for GLP-1 leaders based on updated EPS guidance, product revenue momentum, and ongoing legal/regulatory friction around advertising.
What to watch
The updated EPS range is lower at the top end versus the prior range ($36.00 vs $36.50), and the article notes no further Jardiance milestones remain, which could pressure future quarters despite strong Mounjaro and Zepbound growth.
Background
Lilly’s Q3 2026 earnings included a third guidance increase for the year, with obesity-care revenue growth driven by Mounjaro and Zepbound and additional launches/coverage expansion.
Ticker impact
Eli Lilly raised full-year underlying non-GAAP EPS guidance to $35.00-$36.00 and lifted outlook for a third time in Q3 2026.
Likely upward bias as the market reprices higher full-year EPS expectations, partially offset by lower realized prices and one-time Jardiance milestone benefits.
The article reports a third guidance increase, specific updated EPS range, and product revenue growth, alongside realized price declines and the note that no further Jardiance milestones remain.
Market effects
Reinforces bullish read-through for GLP-1 obesity-care demand and competitive intensity in branded weight-loss advertising.
US-focused demand signals may support US pharma sentiment and obesity-care peer positioning.
Global launch and coverage expansion details suggest continued international uptake beyond the US.
Counterpoint
Realized prices fell 15% and Jardiance benefits are largely front-loaded, so the guidance raise may rely on mix and timing rather than durable pricing power.
Key entities
- companyEli Lilly
Raised full-year underlying non-GAAP EPS guidance for a third time in Q3 2026 earnings; reported strong Mounjaro and Zepbound revenue growth.
- companyNovo Nordisk
Filed a lawsuit over weight-loss drug advertising comparisons; a federal judge denied its request to halt Lilly’s advertising.
